LumaLex Law | Dustin Robinson
On September 18, 2026, FDA issued a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, following an inspection of its Houston 503A facility conducted November 3 through 14, 2025. The letter is worth reading in full, because it does something FDA has mostly avoided until now: it explains, with specifics, why the industry’s standard workaround does not work.
A warning letter states FDA’s position following an inspection. It is not an adjudication. Empower received a Form FDA 483 on November 14, 2025 and submitted responses dated December 8, 2025, March 18, 2026, and April 30, 2026, which FDA reviewed and addressed in the letter. The company has said in other contexts that it disputes characterizations of its practices.
The two conditions
Start with what the law actually requires, because most of the commentary on compounded GLP-1s skips it.
A 503A pharmacy cannot compound, regularly or in inordinate amounts, drug products that are essentially copies of commercially available drugs. Semaglutide and tirzepatide are commercially available. They came off the shortage list — tirzepatide on October 2, 2024, semaglutide on February 21, 2025 — and the enforcement discretion windows closed in spring 2025. Two federal lawsuits challenged those determinations. Both preliminary injunctions were denied.
One exception survives. Under 503A(b)(2), a compounded product is not essentially a copy if there is a change, made for an identified individual patient, which produces for that patient a significant difference from the commercially available product, as determined by the prescribing practitioner.
That is two conditions, not one. The change has to be made for a specific person, and it has to actually do something for that person. Most of the industry has been arguing the first and quietly ignoring the second.
What Empower was doing
The products FDA named are Tirzepatide/Niacinamide injection in two strengths and Semaglutide/Cyanocobalamin injection. Vitamin B3 and vitamin B12, respectively, mixed into the GLP-1.
FDA’s position is that these appear to be essentially copies of the approved semaglutide and tirzepatide products. And the agency went further than it usually does, writing that the volume of products being produced suggests that the differences between the compounded products and the approved ones are pretextual.
That is a strong word for a regulator. It says the additive is not a clinical decision. It is a legal costume.
The evidence FDA collected
This is the part every prescriber and every platform operator should read twice. FDA lists three categories of evidence:
- Orders and prescriptions that contain no prescriber determination of significant difference at all. Not a weak one. None.
- Orders with purported determinations of “significant difference” that appear repeated verbatim across many records — which, FDA says, suggests they may have been pre-generated for selection by the prescriber rather than written by the prescriber for an identified individual patient.
- The sheer volume of particular products compounded and orders filled.
Then FDA names the mechanism directly. Generating prescriptions through means that undermine the individualized nature of a prescriber’s clinical judgment — the letter’s example is third-party technology platforms that give prescribers pre-selected menu options for choosing a statement of significant difference — calls those determinations into question and potentially undermines any claim that they satisfy 503A.
If you operate a telehealth platform and your provider workflow includes a dropdown for the clinical justification, FDA has now described your product in a warning letter.
The catalog is the evidence
Here is where it gets uncomfortable, and where anyone can verify the argument themselves.
As published on Empower’s website at the time of writing, Semaglutide/Cyanocobalamin Injection and Tirzepatide/Niacinamide Injection are listed as products. They appear under Weight Management. They appear under Longevity. They appear under Peptides. They appear on a page labeled Trending Products, beside a link reading View Full Catalog. A separate page announces a price reduction on the Semaglutide/Methylcobalamin ODT of as much as 70%. Provider forms offer a dedicated clinic liaison who will follow up with formulary details, pricing, and next steps.
None of that is unusual for a pharmacy. All of it is difficult to reconcile with patient-specific compounding.
A patient-specific determination is a clinical judgment a prescriber reaches about one person, after evaluating that person. A product in a catalog with a price, a liaison, and a formulary sheet is something else. It existed before the patient did. The prescriber did not design it; the prescriber selected it.
You can hold both ideas at once — that compounded GLP-1s serve real patients, and that a standing SKU cannot be the output of an individualized determination — but the industry has been pretending only the first one matters.
FDA’s three evidence categories map onto that catalog precisely. When the formulation is fixed, the determination becomes boilerplate, because there is nothing individual left to determine. Volume is what happens next. The letter reads as a description of catalog compounding, and the website is the catalog.
Website descriptions here reflect Empower’s public pages as of the date of this post. Sites change; the pages referenced have been archived.
What this means if you are a 503A
Your scale is now evidence against you. That is a genuinely difficult thing to absorb, because scale was previously just a business achievement. Under this letter, high volume of a single formulation is one of the three things FDA points to in concluding that the differences are pretextual.
Second, you are relying on determinations you did not make. The prescriber makes the call, but you are the one holding the records when FDA arrives, and FDA’s guidance directs compounders relying on a prescriber’s determination to ensure it is documented on the prescription. If what you are holding is a hundred thousand identical sentences, you are not holding determinations. You are holding a template.
And note what else is in the letter. This is not solely an essentially-a-copy action. FDA cites insanitary conditions rendering the products adulterated — the examples given are inadequate smoke studies to demonstrate unidirectional airflow in the ISO 5 area, and media fills not performed under the most challenging or stressful conditions. Separately, it cites five CGMP violations, including a quality control unit that failed to exercise its responsibility. Then unapproved new drug and misbranding charges on top. The copy analysis is the headline; the quality findings are what make a letter like this hard to answer.
The documentation theme repeats at the corrective-action stage. FDA writes that it could not fully evaluate certain corrective actions because the firm did not include sufficient information or supporting documentation — specifically, a smoke study executed March 30 through April 3, 2026 that remained in post-execution review with no final summary report provided. Same failure mode as the prescription records. The work may have been done. The record was not there to show it.
What this means if you are a telehealth company
You do not compound, so the instinct is that this is somebody else’s problem. Three reasons it isn’t.
Your intake form is the evidence. FDA’s example of an arrangement that undermines individualized clinical judgment is a third-party technology platform offering pre-selected significant-difference language. That is a description of a product feature, and you probably built it because it reduced provider friction.
Your pharmacy is your product. If your compounding partner’s 503A exemption fails, the drugs it ships are unapproved and misbranded, and your supply stops. Diligence on your pharmacy’s regulatory posture is not a nice-to-have.
And FDA is already working your end of the chain. In March 2026, the agency sent warning letters to 30 telehealth companies over claims about compounded GLP-1s. Now it has hit the largest compounder in the country. The pattern is not subtle.
What a defensible determination looks like
Short version. It names a specific finding about a specific patient — a documented intolerance, a documented lab abnormality, a titration problem, a strength the commercial product does not offer. It says how that finding was established, with a date. It explains why the change addresses that finding and why the commercial product will not work for this person. It is written on the prescription, not only buried in a chart. And it does not read identically to the note written for the patient before.
The test is simple and unforgiving: if you printed a hundred of your determinations and laid them side by side, would they look like a hundred clinical judgments, or one sentence copied a hundred times?
FDA has now told you which one it is looking for.
This post is general information for educational purposes. It is not legal advice, does not create an attorney-client relationship, and is not a substitute for advice about your specific circumstances. Source: FDA Warning Letter, MARCS-CMS 738238, September 18, 2026.
